Episode Details
Back to Episodes
Cannabis Industry Navigates Federal Rescheduling and State Oversupply Pressures
Published 3 months, 4 weeks ago
Description
In the past 48 hours, the cannabis industry shows cautious optimism amid federal rescheduling momentum, though state-level oversupply pressures persist. On December 29, MarketBeat highlighted high trading volume in key stocks like Tilray Brands (TLRY), Canopy Growth (CGC), Aurora Cannabis (ACB), SNDL, Akanda (AKAN), Cronos Group (CRON), and Organigram (OGI), signaling investor interest without major price surges[4].
Federal developments dominate: President Trumps December 18 Executive Order directed marijuana rescheduling to Schedule III, potentially unlocking tax deductions and research by 2026 or 2027[2][6][13][14]. Critics, including some Republicans, argue it hands billions in tax relief to large operators, while the DOJ might sidestep full implementation[8][14]. The FDA plans to maintain strict hemp and marijuana botanical guidance despite the order[10]. Research breakthroughs are anticipated post-rescheduling, addressing decades of barriers[13].
In Oregon, a stark contrast: Croptober 2025 harvest hit a record 6,289,890 pounds, up 8.9 percent from 2024s peak, deepening price depression[2]. Producer licenses dipped slightly to 1,351 from 1,375 year-over-year, with sales at 60,000 to 85,000 dollars, often to Chinese buyers[2]. New rules ban most CBN products without FDA nods, effective July 2025, and licensing tweaks launch January 1, 2026[2].
No major deals, partnerships, or product launches surfaced in the last 48 hours. Consumer behavior shifts remain subtle, with soft markets prompting compliance pivots by regulators like Oregons OLCC, favoring education over punishment for small operators[2]. Leaders like the Cannabis Industry Alliance of Oregon lobbied successfully for transfer rights and enforcement flexibility earlier in 2025[2].
Compared to prior weeks, rescheduling hype sustains stock buzz from mid-December, but Oregons harvest glut worsens supply chain woes versus 2024s already record output. Industry executives eye tax strategies, with partnerships and S-corps potentially converting to C-corps for benefits[6][12]. Overall, federal tailwinds clash with regional oversupply, positioning 2026 as pivotal.
(Word count: 298)
For great deals today, check out https://amzn.to/44ci4hQ
This content was created in partnership and with the help of Artificial Intelligence AI
Federal developments dominate: President Trumps December 18 Executive Order directed marijuana rescheduling to Schedule III, potentially unlocking tax deductions and research by 2026 or 2027[2][6][13][14]. Critics, including some Republicans, argue it hands billions in tax relief to large operators, while the DOJ might sidestep full implementation[8][14]. The FDA plans to maintain strict hemp and marijuana botanical guidance despite the order[10]. Research breakthroughs are anticipated post-rescheduling, addressing decades of barriers[13].
In Oregon, a stark contrast: Croptober 2025 harvest hit a record 6,289,890 pounds, up 8.9 percent from 2024s peak, deepening price depression[2]. Producer licenses dipped slightly to 1,351 from 1,375 year-over-year, with sales at 60,000 to 85,000 dollars, often to Chinese buyers[2]. New rules ban most CBN products without FDA nods, effective July 2025, and licensing tweaks launch January 1, 2026[2].
No major deals, partnerships, or product launches surfaced in the last 48 hours. Consumer behavior shifts remain subtle, with soft markets prompting compliance pivots by regulators like Oregons OLCC, favoring education over punishment for small operators[2]. Leaders like the Cannabis Industry Alliance of Oregon lobbied successfully for transfer rights and enforcement flexibility earlier in 2025[2].
Compared to prior weeks, rescheduling hype sustains stock buzz from mid-December, but Oregons harvest glut worsens supply chain woes versus 2024s already record output. Industry executives eye tax strategies, with partnerships and S-corps potentially converting to C-corps for benefits[6][12]. Overall, federal tailwinds clash with regional oversupply, positioning 2026 as pivotal.
(Word count: 298)
For great deals today, check out https://amzn.to/44ci4hQ
This content was created in partnership and with the help of Artificial Intelligence AI